8-K
filed November 2, 2023, 7:59 PM ET
ticker VVOS
CIK 0001716166
other material
confidence high
sentiment neutral
materiality 0.60
Vivos raises $4.0M via private placement of stock and warrants; amends prior warrant
Vivos Therapeutics, Inc.
- Sold 980,393 shares (or pre-funded warrants) at $4.08/share plus 980,393 Series A and 980,393 Series B warrants at $3.83.
- Net proceeds of ~$3.5M for working capital and corporate purposes.
- Amended January 2023 warrant held by same investor: exercise price cut from $30 to $3.83, expiration extended to Nov 2, 2028.
- Registration rights agreement requires filing within 20 days; penalties up to 10.5% of gross proceeds for delay.
- A.G.P./Alliance Global Partners acted as placement agent with 7% cash fee.
Key facts
Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vivos Therapeutics, Inc. amended January 2023 Warrant Amendment with the Purchaser (effective 2023-11-02).
- Action
- amendment
- Agreement
- equity purchase
- Counterparty
- the Purchaser
- Effective
- 2023-11-02
Exact text from the filing
Such amendment (the “ January 2023 Warrant Amendment ”), which became effective upon the closing of the Private Placement, reduced the exercise price of the January 2023 Warrant to $3.83 per share and extended the expiration date of the January 2023 Warrant to November 2, 2028.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vivos Therapeutics, Inc. entered into Registration Rights Agreement with the Purchaser (effective 2023-11-02).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Purchaser
- Effective
- 2023-11-02
Exact text from the filing
On the Closing Date, in connection with the Private Placement, the Company entered into a registration rights agreement with the Purchaser (the “ Registration Rights Agreement ”), pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “ SEC ”) covering the resale of the Shares and the shares of Common Stock issuable upon exercise of the Warrants within 20 days of the Closing Date
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vivos Therapeutics, Inc. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners (effective 2023-10-30).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- A.G.P./Alliance Global Partners
- Effective
- 2023-10-30
Exact text from the filing
Pursuant to a placement agency agreement dated October 30, 2023, between the Company and the Placement Agent (the “ Placement Agency Agreement ”), the Company agreed to pay to the Placement Agent a cash fee equal to 7.0% of the gross proceeds received by the Company in the Private Placement
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with an institutional investor valued at $4,000,003.44 (effective 2023-10-30).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- an institutional investor
- Value
- $4,000,003.44
- Effective
- 2023-10-30
Exact text from the filing
On October 30, 2023, Vivos Therapeutics, Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an institutional investor (the “ Purchaser ”) pursuant to which the Company agreed sell an aggregate of $4,000,003.44 of securities of the Company in a private placement
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.